Hikma制药
成立一年
1978年阶段
首次公开募股 |上市上市日期
10/17/2005缺失:Hikma制药的产品演示和案例研究
促进你的产品提供技术买家。
达到1000年代的买家使用CB的见解来确定供应商,演示产品,德赢体育vwin官方网站做出购买决定。
缺失:Hikma制药的产品&微分器
不要让你的产品被跳过。买家使用我们的供应商排名名单公司和驱动(rfp)请求建议。
最新的Hikma制药新闻
2023年6月21日
市场驱动和限制:全球纳洛酮市场收入是由患病率的增加阿片类药物滥用和过量,对纳洛酮的意识上升,和政府举措促进纳洛酮的使用。此外,努力增加获得药物和可用性不同配方的纳洛酮为市场收入增长作出贡献。然而,缺乏对使用预计纳洛酮抑制全球纳洛酮市场的收入增长。要求定制——https://www.growthplusreports.com/inquiry/customization/naloxone-market/8716应用程序分割的基础上应用,全球纳洛酮市场划分为阿片类药物过量,酒精过量。由于高发病率和死亡率的情况下,阿片类药物过量部分占最大的市场收入份额。纳洛酮是主要的治疗和一个快速和有效的阿片拮抗物。分割,根据给药途径给药途径,全球纳洛酮市场被分割为注射,鼻腔和口腔。鼻路线的政府部分占最大的收入份额由于容易使用,non-invasiveness和高便利。分割基于分销渠道的分销渠道,全球纳洛酮市场被分割为医院药房,零售药店,网上药店。零售药店段占最大的收入份额由于缓解所需的可用性的药物和主动提供纳洛酮。 Regional Growth Dynamics Based on the region, the global naloxone market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. Due to rising public awareness, sophisticated healthcare infrastructure, and greater demand for medications due to overdose of opioids, North America accounts for the largest revenue share in the global market. Report Coverage Growth Plus Reports studied the global market for naloxone in-depth. Basic market features, important investment sectors, analyses of regional growth, revenue projections, rival market participants, and mergers and acquisitions were all examined. Table of Content Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction Visit our report store at - https://www.growthplusreports.com/report-store Browse more latest healthcare reports: COMT Inhibitors Market by Drugs (Entacapone, Tolcapone), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031 Neurofibromatosis Market by Type (NF1, NF2), Drug Class (Antihistamines, Antineoplastic Agents), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031 Synthetic Ovulation Stimulants Market by Drug Class (Clomiphene Citrate (CC), Aromatase Inhibitors, GnRH Analogs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Outlook and Forecast 2023-2031 Rasburicase Market by Indication (Leukemia, Lymphoma, Solid Tumor Malignancies, Others), Patient Type (Adult, Pediatric) – Global Outlook & Forecast 2023-2031 Antipsoriatics Market by Type (Plaque Psoriasis, Psoriatic Arthritis), Drug Type (TNF Inhibitors, Interleukins, Retinoids), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) -Global Outlook & Forecast 2023-2031 About Us: Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020". Tags
Hikma制药常见问题(FAQ)
Hikma制药是何时成立的?
Hikma医药成立于1978年。
Hikma制药的总部在哪里?
Hikma制药总部位于1新伯灵顿,伦敦。
Hikma制药的最新一轮融资是什么?
Hikma制药的最新一轮融资是上市。
发现正确的解决方案为您的团队
CB见解德赢体育vwin官方网站科技市场情报平台分析数百万数据点在供应商、产品、合作关系,专利来帮助您的团队发现他们的下一个技术解决方案。